Clinical Efficacy of Spray-Type Nasal Allergen Blocker as Adjuvant Treatment for Pediatric Allergic Rhinitis

Area of Science:

• Allergy and Immunology
• Otolaryngology
• Pediatric Medicine

Background:

• Pediatric allergic rhinitis (AR) significantly impacts children's quality of life.
• Current treatments like Mometasone Furoate Aqueous Nasal Spray offer relief but may have limitations.
• Adjuvant therapies are being explored to enhance AR management.

Purpose of the Study:

• To assess the clinical effectiveness of a Spray-Type Nasal Allergen Blocker as an add-on treatment for pediatric AR.
• To compare the efficacy of Mometasone Furoate Aqueous Nasal Spray alone versus in combination with the nasal allergen blocker.

Main Methods:

• A retrospective study included 82 pediatric patients (4-14 years) with AR.
• Patients were divided into two groups: Mometasone Furoate Aqueous Nasal Spray alone (n=38) and combination therapy (n=44).
• Outcomes evaluated after 4 weeks included total effective rate, immune markers (IFN-γ, TGF-β), nasal function, and quality of life (RQLQ).

Main Results:

• The combination group showed higher total effective rates and improved serum IFN-γ and TGF-β levels.
• Nasal ventilation area and ciliary movement rate were significantly better in the combination group.
• Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) scores improved, and Total Nasal Symptom Score (TNSS) and nasal resistance decreased in the combination group (P < .05).

Conclusions:

• The combination of Spray-Type Nasal Allergen Blocker and Mometasone Furoate Aqueous Nasal Spray is a promising adjuvant therapy for pediatric AR.
• This combined approach demonstrated superior clinical efficacy compared to Mometasone Furoate Aqueous Nasal Spray monotherapy.
• The findings suggest a potential benefit for improving nasal symptoms and quality of life in children with AR.